Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

(NASDAQ:LSTA), Cash runway extending into the fourth quarter of 2026 with no debt, funding current clinical programs through to their next data milestone Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company […]

Fox Factory Holding Corp. Reports Second Quarter Fiscal 2025 Financial Results

Fox Factory Holding Corp. Reports Second Quarter Fiscal 2025 Financial Results GlobeNewswire August 07, 2025 DULUTH, Ga., Aug. 07, 2025 (GLOBE NEWSWIRE) — Fox Factory Holding Corp. (NASDAQ: FOXF) (“FOX” or the “Company”), a premium brand and a global leader in the design, engineering and manufacturing of performance-defining products and systems for customers worldwide, today

ICU Medical Announces Second Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance

(NASDAQ:ICUI), SAN CLEMENTE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) — ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2025. Second Quarter 2025 Results Second quarter 2025 revenue was $548.9 million, as compared to $596.5 million in

ARMOUR Residential REIT, Inc. Announces Closing of Public Offering of 18,500,000 Shares of Common Stock

ARMOUR Residential REIT, Inc. Announces Closing of Public Offering of 18,500,000 Shares of Common Stock GlobeNewswire August 07, 2025 VERO BEACH, Florida, Aug. 07, 2025 (GLOBE NEWSWIRE) — ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) (“ARMOUR” or the “Company”) today announced that it has closed an underwritten public offering of 18,500,000 shares of its

Concentrix to Present at Upcoming Investor Conferences

Concentrix to Present at Upcoming Investor Conferences GlobeNewswire August 07, 2025 NEWARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) — Concentrix Corporation (NASDAQ: CNXC), a global technology and services leader, today announced that members of its senior executive team will be participating in the following upcoming conferences: Canaccord Genuity 45th Annual Growth Conference – Tuesday August

Scientific Industries Completes Strategic Refocus and Secures Proceeds of $10 million to Accelerate Growth of Two Data-Driven Business Platforms; Divests Genie(R) Division to OHAUS Corporation’s affiliate Troemner, LLC

Scientific Industries Completes Strategic Refocus and Secures Proceeds of $10 million to Accelerate Growth of Two Data-Driven Business Platforms; Divests Genie(R) Division to OHAUS Corporation's affiliate Troemner, LLC GlobeNewswire August 07, 2025 Realign priorities – AI-powered platforms to accelerate innovation and market leadership Driving transformation in pharmacy automation with VIVID's advanced solutions Advancing AI-powered biomanufacturing

Commerce to Host Sell-side Analyst Q&A Session at Upcoming BigSummit

Commerce to Host Sell-side Analyst Q&A Session at Upcoming BigSummit GlobeNewswire August 07, 2025 AUSTIN, Texas, Aug. 07, 2025 (GLOBE NEWSWIRE) — Commerce.com, Inc. (Nasdaq: CMRC) (formerly BigCommerce Holdings, Inc.), a provider of an open, intelligent ecosystem of technology solutions that empower businesses to unlock data potential and deliver seamless, personalized experiences at scale, today

Portman Ridge Finance Corporation Announces Second Quarter 2025 Financial Results

Portman Ridge Finance Corporation Announces Second Quarter 2025 Financial Results GlobeNewswire August 07, 2025 Completed Merger with Logan Ridge Finance Corporation Reports Net Investment Income of $4.6 Million, or $0.50 Per Share for the Second Quarter Announces Third Quarter 2025 Quarterly Base Distribution of $0.47 Per Share and Supplemental Distribution of $0.02 per share NEW

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

(NASDAQ:NXTC), Announced strategic partnership with Simcere Zaiming for Phase 1 program SIM0505 (CDH6 ADC) with plans to dose the first SIM0505 patient in the United States this quarter Currently in cohort 4 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers Plan to provide SIM0505 and LNCB74 program updates by the fourth

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

(NASDAQ:ZYME), Investigational new drug (IND) application cleared by the United States Food and Drug Administration (FDA) for ZW251 with first-in-human studies planned to initiate in 2025 China and European approval for zanidatamab in 2L HER2-positive biliary tract cancer (BTC) expands international patient access $48.7 million in revenue for 2Q-2025 from continued progress on existing partnerships

Scroll to Top